The filing contains no new pricing, binary data readout, or financing news — it is a standard clinical update and investor relations event. The $6.1M cash position offers limited visibility (~3 quarters at burn rate) before needing further ATM draws or dilutive financing. Key catalysts to watch are the FDA Type C meeting request timing, Australian site expansions, and the Phase IIa data readout expected later in 2026.
Price Chart
Executive Summary
Oragenics filed an 8-K with a shareholder update and investor presentation ahead of the Sidoti Micro-Cap Conference. The update confirms the Phase IIa trial of ONP-002 for concussion is actively enrolling in Australia with no serious adverse events, the signing of a Letter of Intent for a CNS medical device license, and a Q1 2026 cash balance of $6.1 million. However, the company continues to rely on its ATM facility for funding, with no disclosed revenue and high cash burn visibility (~3 quarters at current R&D and G&A run rate of ~$2.2M/quarter), making this a routine clinical-stage pipeline update with no new material financial or binary catalyst data.
Key Facts
- Phase IIa trial of ONP-002 for concussion active in Australia; first patient dosed at Mackay Base Hospital with zero serious adverse events recorded so far.
- Signed a Letter of Intent for a licensing agreement for a complementary CNS-related medical device; deal structure carves out TBI indication rights for Oragenics.
- Q1 2026 cash balance of $6.1 million; R&D expenses of $0.6 million (up 89% from same period in 2025); G&A expenses of $1.6 million (down 4% YoY).
- ATM facility active; new S-3 filed January 2026 with SEC review completed; ATM activity generated proceeds in Q1 2026.
- Targeting Type C Meeting Request to FDA in Q2 2026 and full IND submission by end of 2026 to enable US-based trials in 2027.
- 40-patient enrollment target for Phase IIa; randomized, placebo-controlled; primary endpoints are safety, tolerability, and feasibility.
- Annual shareholder meeting scheduled for June 29, 2026.
Financial Impact
Q1 2026 cash of $6.1 million against quarterly operating expenses of approximately $2.2 million (R&D $0.6M + G&A $1.6M) provides roughly 3 quarters of runway without additional capital raises.
Risk Factors
- Cash runway limited to approximately 3 quarters at current burn rate without additional capital raises via ATM or dilutive offerings.
- Phase IIa trial has a small 40-patient target; early-stage clinical data may not support FDA IND or later-stage success.
- Letter of Intent for licensing is non-binding and may not result in a definitive agreement.
- No FDA-approved pharmacological treatment currently exists for mTBI; regulatory pathway is uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024363 |
| Exhibit: ex99-2.htm | 0001493152-26-024363 |
| Exhibit: ex99-3.htm | 0001493152-26-024363 |
| Document: 0001493152-26-024363-index-headers.html | 0001493152-26-024363 |
| Document: 0001493152-26-024363-index.html | 0001493152-26-024363 |
| Document: 0001493152-26-024363.txt | 0001493152-26-024363 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 5w ago | 8-K | $0.5000 $0.4469 | ▼ −10.62% | ▼ −13.80% | $0.3700 (−26.00%) |
Aug 28, 2026 8w ago | 8-K | $0.5098 $0.4800 | ▲ +5.85% | ▲ +5.66% | $0.3700 (+27.42%) |
May 20, 2026 22w ago | DEFA14A | $0.5900 $0.5882 | ▼ −0.31% | ▼ −0.64% | $0.3700 (−37.29%) |
May 19, 2026 23w ago | 8-K | $0.5700 $0.6100 | ▲ +7.02% | ▲ +6.03% | $0.3700 (−35.09%) |
May 7, 2026 24w ago | 8-K | $0.6100 $0.6100 | · 0.00% | ▼ −3.14% | $0.3700 (−39.34%) |
Apr 13, 2026 28w ago | 8-K | $0.6800 $0.5600 | ▼ −17.65% | ▼ −25.38% | $0.3700 (−45.59%) |
Mar 25, 2026 30w ago | Press Release | $0.5800 $0.6400 | ▼ −10.34% | ▲ +0.32% | $0.3700 (+36.21%) |
Mar 23, 2026 31w ago | EFFECT | $0.6800 $0.6600 | ▼ −2.94% | ▼ −10.36% | $0.3700 (−45.59%) |
Mar 11, 2026 32w ago | 8-K | $0.9600 $0.6000 | ▼ −37.50% | ▼ −39.48% | $0.3700 (−61.46%) |
Mar 11, 2026 32w ago | Press Release | $0.8800 $0.6200 | ▼ −29.55% | ▼ −30.07% | $0.3700 (−57.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers